BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 25865094)

  • 1. Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.
    Garnacho-Montero J; Amaya-Villar R; Ferrándiz-Millón C; Díaz-Martín A; López-Sánchez JM; Gutiérrez-Pizarraya A
    Expert Rev Anti Infect Ther; 2015 Jun; 13(6):769-77. PubMed ID: 25865094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
    Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
    J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
    Liu CP; Shih SC; Wang NY; Wu AY; Sun FJ; Chow SF; Chen TL; Yan TR
    J Microbiol Immunol Infect; 2016 Dec; 49(6):934-940. PubMed ID: 25553994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study.
    Lee NY; Wang CL; Chuang YC; Yu WL; Lee HC; Chang CM; Wang LR; Ko WC
    Pharmacotherapy; 2007 Nov; 27(11):1506-11. PubMed ID: 17963460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome.
    Kim NH; Hwang JH; Song KH; Choe PG; Kim ES; Park SW; Kim HB; Kim NJ; Park WB; Oh MD
    Scand J Infect Dis; 2013 Apr; 45(4):315-9. PubMed ID: 23113680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
    Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
    J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OXA-type Carbapenemases and Susceptibility of Colistin and Tigecycline Among Carbapenem-Resistant Acinetobacter Baumannii Isolates from Patients with Bacteremia in Turkey.
    Cakirlar FK; Ciftci IH; Gonullu N
    Clin Lab; 2015; 61(7):741-7. PubMed ID: 26299073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU.
    Sheng WH; Wang JT; Li SY; Lin YC; Cheng A; Chen YC; Chang SC
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):380-6. PubMed ID: 21558048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
    Park GC; Choi JA; Jang SJ; Jeong SH; Kim CM; Choi IS; Kang SH; Park G; Moon DS
    Ann Lab Med; 2016 Mar; 36(2):124-30. PubMed ID: 26709259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii.
    Ni W; Cui J; Liang B; Cai Y; Bai N; Cai X; Wang R
    J Antibiot (Tokyo); 2013 Dec; 66(12):705-8. PubMed ID: 23981963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.
    Cheng A; Chuang YC; Sun HY; Sheng WH; Yang CJ; Liao CH; Hsueh PR; Yang JL; Shen NJ; Wang JT; Hung CC; Chen YC; Chang SC
    Crit Care Med; 2015 Jun; 43(6):1194-204. PubMed ID: 25793437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
    Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.
    Song JY; Kee SY; Hwang IS; Seo YB; Jeong HW; Kim WJ; Cheong HJ
    J Antimicrob Chemother; 2007 Aug; 60(2):317-22. PubMed ID: 17540672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections.
    Ku K; Pogue JM; Moshos J; Bheemreddy S; Wang Y; Bhargava A; Campbell M; Khandker N; Lephart PR; Chopra T; Hayakawa K; Martin ET; Abreu-Lanfranco O; Dhar S; Kaye KS; Marchaim D
    Am J Infect Control; 2012 Dec; 40(10):983-7. PubMed ID: 22440526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-polymyxin-based combinations as potential alternatives in treatment against carbapenem-resistant Acinetobacter baumannii infections.
    Mohd Sazlly Lim S; Naicker S; Ayfan AK; Zowawi H; Roberts JA; Sime FB
    Int J Antimicrob Agents; 2020 Oct; 56(4):106115. PubMed ID: 32721600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant
    Niu T; Luo Q; Li Y; Zhou Y; Yu W; Xiao Y
    Antimicrob Resist Infect Control; 2019; 8():52. PubMed ID: 30886705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.
    Khawcharoenporn T; Pruetpongpun N; Tiamsak P; Rutchanawech S; Mundy LM; Apisarnthanarak A
    Int J Antimicrob Agents; 2014 Apr; 43(4):378-82. PubMed ID: 24613422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: A multi-centre clinical experience.
    Russo A; Gullì SP; D'Avino A; Borrazzo C; Carannante N; Dezza FC; Covino S; Polistina G; Fiorentino G; Trecarichi EM; Mastroianni CM; Torti C; Oliva A
    Int J Antimicrob Agents; 2024 Jul; 64(1):107190. PubMed ID: 38697579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of skin and soft tissue infection due to carbapenem-resistant Acinetobacter baumannii by ampicillin-sulbactam and meropenem combination therapy.
    Hiraki Y; Yoshida M; Masuda Y; Inoue D; Tsuji Y; Kamimura H; Karube Y; Takaki K; Kawano F
    Int J Infect Dis; 2013 Dec; 17(12):e1234-6. PubMed ID: 23791858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis.
    Dinc G; Demiraslan H; Elmali F; Ahmed SS; Metan G; Alp E; Doganay M
    Chemotherapy; 2013; 59(5):325-9. PubMed ID: 24525528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.